Last 12 months
Inside the activity.
0 purchase rows · 214 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 14 |
| Dec 2025 | 0 | 10 |
| Jan 2026 | 0 | 3 |
| Feb 2026 | 0 | 3 |
| Mar 2026 | 0 | 26 |
| Apr 2026 | 0 | 14 |
| May 2026 | 0 | 28 |
| Jun 2026 | 0 | 15 |
| Jul 2026 | 0 | 36 |
| Aug 2026 | 0 | 44 |
| Sep 2026 | 0 | 15 |
| Oct 2026 | 0 | 6 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 30, 2021 Filed Mar 31, 2021 20:13 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 9,438 | $61.92 | $584,410.40 |
DisclosureSEC source: 0001447362-21-000065 · wf-form4_161722161264349.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 652,262 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $61.600 to $62.350, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 30, 2021 Filed Mar 31, 2021 20:13 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 4,114 | $60.99 | $250,916.97 |
DisclosureSEC source: 0001447362-21-000065 · wf-form4_161722161264349.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 661,700 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $60.590 to $61.580, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 30, 2021 Filed Mar 31, 2021 20:13 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 700 | $59.94 | $41,954.50 |
DisclosureSEC source: 0001447362-21-000065 · wf-form4_161722161264349.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 665,814 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $59.480 to $60.460, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 30, 2021 Filed Mar 31, 2021 20:13 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 1,300 | $58.57 | $76,134.50 |
DisclosureSEC source: 0001447362-21-000065 · wf-form4_161722161264349.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 666,514 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $58.100 to $58.945, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 30, 2021 Filed Mar 31, 2021 20:13 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 1,322 | $56.99 | $75,336.81 |
DisclosureSEC source: 0001447362-21-000065 · wf-form4_161722161264349.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 667,814 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $56.690 to $57.500, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 29, 2021 Filed Mar 30, 2021 21:08 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 1,734 | $59.55 | $103,264.90 |
DisclosureSEC source: 0001447362-21-000063 · wf-form4_161713849480029.xml · nonDerivative · entry 6 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 669,136 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F7 · price: This transaction was executed in multiple trades at prices ranging from $59.340 to $60.000, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 29, 2021 Filed Mar 30, 2021 21:08 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 11,240 | $58.85 | $661,462.76 |
DisclosureSEC source: 0001447362-21-000063 · wf-form4_161713849480029.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 670,870 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $58.270 to $59.260, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 26, 2021 Filed Mar 30, 2021 21:08 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 300 | $61.91 | $18,572.10 |
DisclosureSEC source: 0001447362-21-000063 · wf-form4_161713849480029.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 682,110 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $61.860 to $61.930, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 26, 2021 Filed Mar 30, 2021 21:08 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 6,200 | $61.19 | $379,371.80 |
DisclosureSEC source: 0001447362-21-000063 · wf-form4_161713849480029.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 682,410 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $60.830 to $61.750, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 26, 2021 Filed Mar 30, 2021 21:08 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 1,800 | $60.42 | $108,759.60 |
DisclosureSEC source: 0001447362-21-000063 · wf-form4_161713849480029.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 688,610 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $59.800 to $60.795, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 26, 2021 Filed Mar 30, 2021 21:08 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 4,975 | $59.46 | $295,833.40 |
DisclosureSEC source: 0001447362-21-000063 · wf-form4_161713849480029.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 690,410 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $58.800 to $59.790, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 25, 2021 Filed Mar 26, 2021 20:45 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 200 | $62.36 | $12,472.00 |
DisclosureSEC source: 0001447362-21-000061 · wf-form4_161679149902936.xml · nonDerivative · entry 8 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 320,993 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| March 25, 2021 Filed Mar 26, 2021 20:45 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 2,965 | $61.73 | $183,020.56 |
DisclosureSEC source: 0001447362-21-000061 · wf-form4_161679149902936.xml · nonDerivative · entry 7 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 321,193 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F9 · price: This transaction was executed in multiple trades at prices ranging from $61.280 to $62.235, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| March 25, 2021 Filed Mar 26, 2021 20:45 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 3,439 | $60.69 | $208,723.23 |
DisclosureSEC source: 0001447362-21-000061 · wf-form4_161679149902936.xml · nonDerivative · entry 6 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 324,158 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F8 · price: This transaction was executed in multiple trades at prices ranging from $60.280 to $61.080, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| March 25, 2021 Filed Mar 26, 2021 20:45 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 896 | $59.93 | $53,699.07 |
DisclosureSEC source: 0001447362-21-000061 · wf-form4_161679149902936.xml · nonDerivative · entry 5 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 327,597 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F7 · price: This transaction was executed in multiple trades at prices ranging from $59.270 to $60.230, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| March 24, 2021 Filed Mar 26, 2021 20:45 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 1,210 | $64.68 | $78,264.01 |
DisclosureSEC source: 0001447362-21-000061 · wf-form4_161679149902936.xml · nonDerivative · entry 4 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 328,493 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $64.380 to $65.315, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| March 24, 2021 Filed Mar 26, 2021 20:45 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 3,080 | $63.71 | $196,220.64 |
DisclosureSEC source: 0001447362-21-000061 · wf-form4_161679149902936.xml · nonDerivative · entry 3 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 329,703 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $63.310 to $64.145, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| March 24, 2021 Filed Mar 26, 2021 20:45 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 1,310 | $62.88 | $82,372.80 |
DisclosureSEC source: 0001447362-21-000061 · wf-form4_161679149902936.xml · nonDerivative · entry 2 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 332,783 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $62.310 to $63.305, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| March 24, 2021 Filed Mar 26, 2021 20:45 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 1,900 | $61.21 | $116,289.50 |
DisclosureSEC source: 0001447362-21-000061 · wf-form4_161679149902936.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 334,093 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $60.690 to $61.530, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| March 22, 2021 Filed Mar 23, 2021 21:29 UTC |
KABAKOFF DAVID SDirector
|
SaleCommon Stock | 10,000 | $67.12 | $671,212.00 |
DisclosureSEC source: 0001447362-21-000059 · wf-form4_161653494158788.xml · nonDerivative · entry 2 KABAKOFF DAVID S · CIK 0001024008 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By L.P. Disclosed balance after: 733,577 F1 · kind: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Sofinnova HealthQuest Partners, L.P. on December 17, 2020. F2 · ownership.nature: Held by Sofinnova HealthQuest Partners, L.P., or HealthQuest Partners. HealthQuest Venture Management, L.L.C., or HealthQuest Management, is the general partner of HealthQuest Partners. David Kabakoff, Ph.D., the Reporting Person, is a partner of HealthQuest Management. Garheng Kong is the managing member of HealthQuest Management and has sole voting and investment power over the shares held by HealthQuest Partners. Each of HealthQuest Management, Mr. Kong and Dr. Kabakoff disclaims beneficial ownership over all shares held by HealthQuest Partners except to the extent of any pecuniary interest therein. Read SEC document |
| March 19, 2021 Filed Mar 23, 2021 21:29 UTC |
KABAKOFF DAVID SDirector
|
SaleCommon Stock | 10,000 | $66.17 | $661,699.00 |
DisclosureSEC source: 0001447362-21-000059 · wf-form4_161653494158788.xml · nonDerivative · entry 1 KABAKOFF DAVID S · CIK 0001024008 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By L.P. Disclosed balance after: 743,577 F1 · kind: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Sofinnova HealthQuest Partners, L.P. on December 17, 2020. F2 · ownership.nature: Held by Sofinnova HealthQuest Partners, L.P., or HealthQuest Partners. HealthQuest Venture Management, L.L.C., or HealthQuest Management, is the general partner of HealthQuest Partners. David Kabakoff, Ph.D., the Reporting Person, is a partner of HealthQuest Management. Garheng Kong is the managing member of HealthQuest Management and has sole voting and investment power over the shares held by HealthQuest Partners. Each of HealthQuest Management, Mr. Kong and Dr. Kabakoff disclaims beneficial ownership over all shares held by HealthQuest Partners except to the extent of any pecuniary interest therein. Read SEC document |
| March 18, 2021 Filed Mar 22, 2021 20:04 UTC |
Cook Joseph C. IIIDirector
|
Exercise / conversionStock option (right to buy) · Derivative | 12,229 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001447362-21-000057 · wf-form4_161644347105756.xml · derivative · entry 4 Cook Joseph C. III · CIK 0001783205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,666 Underlying: Common Stock · 12,229 shares Expires 2029-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the 30,895 shares originally subject to the option vested on August 1, 2020, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| March 18, 2021 Filed Mar 22, 2021 20:04 UTC |
Cook Joseph C. IIIDirector
|
Exercise / conversionCommon Stock | 12,229 | $16.00 | $195,664.00 |
DisclosureSEC source: 0001447362-21-000057 · wf-form4_161644347105756.xml · nonDerivative · entry 1 Cook Joseph C. III · CIK 0001783205 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,407 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 17, 2021 Filed Mar 18, 2021 20:14 UTC |
KABAKOFF DAVID SDirector
|
SaleCommon Stock | 10,000 | $66.14 | $661,365.00 |
DisclosureSEC source: 0001447362-21-000055 · wf-form4_161609844748968.xml · nonDerivative · entry 5 KABAKOFF DAVID S · CIK 0001024008 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By L.P. Disclosed balance after: 753,577 F1 · kind: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Sofinnova HealthQuest Partners, L.P. on December 17, 2020. F3 · ownership.nature: Held by Sofinnova HealthQuest Partners, L.P., or HealthQuest Partners. HealthQuest Venture Management, L.L.C., or HealthQuest Management, is the general partner of HealthQuest Partners. David Kabakoff, Ph.D., the Reporting Person, is a partner of HealthQuest Management. Garheng Kong is the managing member of HealthQuest Management and has sole voting and investment power over the shares held by HealthQuest Partners. Each of HealthQuest Management, Mr. Kong and Dr. Kabakoff disclaims beneficial ownership over all shares held by HealthQuest Partners except to the extent of any pecuniary interest therein. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 20:14 UTC |
KABAKOFF DAVID SDirector
|
SaleCommon Stock | 20,000 | $65.73 | $1,314,566.00 |
DisclosureSEC source: 0001447362-21-000055 · wf-form4_161609844748968.xml · nonDerivative · entry 4 KABAKOFF DAVID S · CIK 0001024008 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By L.P. Disclosed balance after: 763,577 F1 · kind: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Sofinnova HealthQuest Partners, L.P. on December 17, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $65.7011 to $65.7554, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by Sofinnova HealthQuest Partners, L.P., or HealthQuest Partners. HealthQuest Venture Management, L.L.C., or HealthQuest Management, is the general partner of HealthQuest Partners. David Kabakoff, Ph.D., the Reporting Person, is a partner of HealthQuest Management. Garheng Kong is the managing member of HealthQuest Management and has sole voting and investment power over the shares held by HealthQuest Partners. Each of HealthQuest Management, Mr. Kong and Dr. Kabakoff disclaims beneficial ownership over all shares held by HealthQuest Partners except to the extent of any pecuniary interest therein. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 20:14 UTC |
KABAKOFF DAVID SDirector
|
SaleCommon Stock | 40,000 | $64.63 | $2,585,056.00 |
DisclosureSEC source: 0001447362-21-000055 · wf-form4_161609844748968.xml · nonDerivative · entry 3 KABAKOFF DAVID S · CIK 0001024008 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By L.P. Disclosed balance after: 783,577 F1 · kind: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Sofinnova HealthQuest Partners, L.P. on December 17, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $64.4900 to $64.7471, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by Sofinnova HealthQuest Partners, L.P., or HealthQuest Partners. HealthQuest Venture Management, L.L.C., or HealthQuest Management, is the general partner of HealthQuest Partners. David Kabakoff, Ph.D., the Reporting Person, is a partner of HealthQuest Management. Garheng Kong is the managing member of HealthQuest Management and has sole voting and investment power over the shares held by HealthQuest Partners. Each of HealthQuest Management, Mr. Kong and Dr. Kabakoff disclaims beneficial ownership over all shares held by HealthQuest Partners except to the extent of any pecuniary interest therein. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 20:14 UTC |
KABAKOFF DAVID SDirector
|
SaleCommon Stock | 30,000 | $63.76 | $1,912,707.00 |
DisclosureSEC source: 0001447362-21-000055 · wf-form4_161609844748968.xml · nonDerivative · entry 2 KABAKOFF DAVID S · CIK 0001024008 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By L.P. Disclosed balance after: 823,577 F1 · kind: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Sofinnova HealthQuest Partners, L.P. on December 17, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $63.4256 to $63.9355, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by Sofinnova HealthQuest Partners, L.P., or HealthQuest Partners. HealthQuest Venture Management, L.L.C., or HealthQuest Management, is the general partner of HealthQuest Partners. David Kabakoff, Ph.D., the Reporting Person, is a partner of HealthQuest Management. Garheng Kong is the managing member of HealthQuest Management and has sole voting and investment power over the shares held by HealthQuest Partners. Each of HealthQuest Management, Mr. Kong and Dr. Kabakoff disclaims beneficial ownership over all shares held by HealthQuest Partners except to the extent of any pecuniary interest therein. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 20:14 UTC |
KABAKOFF DAVID SDirector
|
SaleCommon Stock | 30,000 | $61.21 | $1,836,351.00 |
DisclosureSEC source: 0001447362-21-000055 · wf-form4_161609844748968.xml · nonDerivative · entry 1 KABAKOFF DAVID S · CIK 0001024008 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By L.P. Disclosed balance after: 853,577 F1 · kind: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Sofinnova HealthQuest Partners, L.P. on December 17, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $61.1168 to $61.3623, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by Sofinnova HealthQuest Partners, L.P., or HealthQuest Partners. HealthQuest Venture Management, L.L.C., or HealthQuest Management, is the general partner of HealthQuest Partners. David Kabakoff, Ph.D., the Reporting Person, is a partner of HealthQuest Management. Garheng Kong is the managing member of HealthQuest Management and has sole voting and investment power over the shares held by HealthQuest Partners. Each of HealthQuest Management, Mr. Kong and Dr. Kabakoff disclaims beneficial ownership over all shares held by HealthQuest Partners except to the extent of any pecuniary interest therein. Read SEC document |
| March 12, 2021 Filed Mar 15, 2021 20:05 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 59 | $67.03 | $3,955.01 |
DisclosureSEC source: 0001447362-21-000053 · wf-form4_161583872171264.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 695,385 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $66.800 to $67.075, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 12, 2021 Filed Mar 15, 2021 20:05 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 1,165 | $66.26 | $77,196.40 |
DisclosureSEC source: 0001447362-21-000053 · wf-form4_161583872171264.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 695,444 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $65.800 to $66.760, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 12, 2021 Filed Mar 15, 2021 20:05 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 2,000 | $65.18 | $130,362.00 |
DisclosureSEC source: 0001447362-21-000053 · wf-form4_161583872171264.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 696,609 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $64.800 to $65.620, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 12, 2021 Filed Mar 15, 2021 20:05 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 6,788 | $64.32 | $436,583.80 |
DisclosureSEC source: 0001447362-21-000053 · wf-form4_161583872171264.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 698,609 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $63.770 to $64.760, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 12, 2021 Filed Mar 15, 2021 20:05 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 4,363 | $63.32 | $276,282.61 |
DisclosureSEC source: 0001447362-21-000053 · wf-form4_161583872171264.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 705,397 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $62.720 to $63.650, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 11, 2021 Filed Mar 12, 2021 21:15 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 800 | $68.55 | $54,838.40 |
DisclosureSEC source: 0001447362-21-000051 · wf-form4_161558370635915.xml · nonDerivative · entry 7 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 709,760 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F8 · price: This transaction was executed in multiple trades at prices ranging from $68.290 to $68.880, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 11, 2021 Filed Mar 12, 2021 21:15 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 9,394 | $67.78 | $636,715.93 |
DisclosureSEC source: 0001447362-21-000051 · wf-form4_161558370635915.xml · nonDerivative · entry 6 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 710,560 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F7 · price: This transaction was executed in multiple trades at prices ranging from $67.280 to $68.240, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 11, 2021 Filed Mar 12, 2021 21:15 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 4,181 | $66.96 | $279,938.86 |
DisclosureSEC source: 0001447362-21-000051 · wf-form4_161558370635915.xml · nonDerivative · entry 5 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 719,954 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $66.280 to $67.235, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 21:15 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 3,685 | $66.22 | $244,009.65 |
DisclosureSEC source: 0001447362-21-000051 · wf-form4_161558370635915.xml · nonDerivative · entry 4 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 724,135 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $65.930 to $66.820, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 21:15 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 5,690 | $65.60 | $373,269.69 |
DisclosureSEC source: 0001447362-21-000051 · wf-form4_161558370635915.xml · nonDerivative · entry 3 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 727,820 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $64.920 to $65.900, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 21:15 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 1,815 | $64.32 | $116,740.80 |
DisclosureSEC source: 0001447362-21-000051 · wf-form4_161558370635915.xml · nonDerivative · entry 2 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 733,510 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $63.880 to $64.870, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 21:15 UTC |
MAETZOLD DEREK JDirector · Pres. & Chief Exec. Officer
|
SaleCommon Stock | 3,185 | $63.26 | $201,495.84 |
DisclosureSEC source: 0001447362-21-000051 · wf-form4_161558370635915.xml · nonDerivative · entry 1 MAETZOLD DEREK J · CIK 0001239501 · Director · Pres. & Chief Exec. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 735,325 F1 · kind: These transactions were made pursuant to Rule 10b5-1 plans adopted by the Reporting Person on September 10, 2020 and December 11, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $62.800 to $63.760, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 09, 2021 Filed Mar 10, 2021 21:08 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 200 | $68.81 | $13,762.00 |
DisclosureSEC source: 0001447362-21-000040 · wf-form4_161541047963828.xml · nonDerivative · entry 11 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 335,993 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| March 09, 2021 Filed Mar 10, 2021 21:08 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 946 | $67.28 | $63,650.66 |
DisclosureSEC source: 0001447362-21-000040 · wf-form4_161541047963828.xml · nonDerivative · entry 10 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 336,193 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F12 · price: This transaction was executed in multiple trades at prices ranging from $66.900 to $67.750, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| March 09, 2021 Filed Mar 10, 2021 21:08 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 383 | $66.02 | $25,286.43 |
DisclosureSEC source: 0001447362-21-000040 · wf-form4_161541047963828.xml · nonDerivative · entry 9 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 337,139 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F11 · price: This transaction was executed in multiple trades at prices ranging from $65.720 to $66.680, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| March 09, 2021 Filed Mar 10, 2021 21:08 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 995 | $65.26 | $64,937.68 |
DisclosureSEC source: 0001447362-21-000040 · wf-form4_161541047963828.xml · nonDerivative · entry 8 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 337,522 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F10 · price: This transaction was executed in multiple trades at prices ranging from $64.710 to $65.690, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| March 09, 2021 Filed Mar 10, 2021 21:08 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 387 | $64.04 | $24,785.03 |
DisclosureSEC source: 0001447362-21-000040 · wf-form4_161541047963828.xml · nonDerivative · entry 7 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 338,517 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F9 · price: This transaction was executed in multiple trades at prices ranging from $63.570 to $64.550, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| March 09, 2021 Filed Mar 10, 2021 21:08 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 1,914 | $62,860.00 | $120,314,040.00 |
DisclosureSEC source: 0001447362-21-000040 · wf-form4_161541047963828.xml · nonDerivative · entry 6 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 338,904 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F8 · price: This transaction was executed in multiple trades at prices ranging from $62.420 to $63.300, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| March 09, 2021 Filed Mar 10, 2021 21:08 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 2,675 | $61.80 | $165,320.35 |
DisclosureSEC source: 0001447362-21-000040 · wf-form4_161541047963828.xml · nonDerivative · entry 5 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 340,818 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F7 · price: This transaction was executed in multiple trades at prices ranging from $61.270 to $62.260, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 21:08 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 1,200 | $68.96 | $82,753.20 |
DisclosureSEC source: 0001447362-21-000040 · wf-form4_161541047963828.xml · nonDerivative · entry 4 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 343,493 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $68.730 to $69.380, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 21:08 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 1,805 | $68.04 | $122,814.01 |
DisclosureSEC source: 0001447362-21-000040 · wf-form4_161541047963828.xml · nonDerivative · entry 3 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 344,693 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $67.620 to $68.450, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 21:08 UTC |
BRADBURY DANIELDirector
|
SaleCommon Stock | 2,795 | $67.10 | $187,544.50 |
DisclosureSEC source: 0001447362-21-000040 · wf-form4_161541047963828.xml · nonDerivative · entry 2 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 346,498 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by BioBrit, LLC (the "LLC") on September 5, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $66.495 to $67.445, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by the LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.